| Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts K Huhtinen, P Suvitie, J Hiissa, J Junnila, J Huvila, H Kujari, M Setälä, ... British journal of cancer 100 (8), 1315-1319, 2009 | 504 | 2009 |
| L1CAM expression in endometrial carcinomas: an ENITEC collaboration study LJM Van Der Putten, N Visser, K Van de Vijver, M Santacana, P Bronsert, ... British journal of cancer 115 (6), 716-724, 2016 | 106 | 2016 |
| Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis J Huvila, J Pors, EF Thompson, CB Gilks The Journal of Pathology 253 (4), 355-365, 2021 | 98 | 2021 |
| Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways T Cuppens, M Moisse, J Depreeuw, D Annibali, E Colas, A Gil‐Moreno, ... International journal of cancer 142 (6), 1230-1243, 2018 | 72 | 2018 |
| Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma J Huvila, L Talve, O Carpén, PH Edqvist, F Pontén, S Grénman, ... Gynecologic oncology 130 (3), 463-469, 2013 | 67 | 2013 |
| Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study C Reijnen, E Gogou, NCM Visser, H Engerud, J Ramjith, ... PLoS medicine 17 (5), e1003111, 2020 | 52 | 2020 |
| Added value of estrogen receptor, progesterone receptor, and L1 cell adhesion molecule expression to histology-based endometrial carcinoma recurrence prediction models: an … LJM Van Der Putten, NCM Visser, K Van de Vijver, M Santacana, ... International Journal of Gynecologic Cancer 28 (3), 2018 | 52 | 2018 |
| p53abn endometrial cancer: understanding the most aggressive endometrial cancers in the era of molecular classification A Jamieson, EF Thompson, J Huvila, CB Gilks, JN McAlpine International Journal of Gynecologic Cancer 31 (6), 2021 | 45 | 2021 |
| Potential targets' analysis reveals dual PI3K/mTOR pathway inhibition as a promising therapeutic strategy for uterine leiomyosarcomas—an ENITEC Group Initiative T Cuppens, D Annibali, A Coosemans, J Trovik, N Ter Haar, E Colas, ... Clinical Cancer Research 23 (5), 1274-1285, 2017 | 35 | 2017 |
| Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors J Huvila, A Brandt, CR Rojas, S Pasanen, L Talve, P HirsimÄKi, V Fey, ... International Journal of Gynecologic Cancer 19 (7), 2009 | 34 | 2009 |
| The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types P Micke, C Strell, J Mattsson, A Martín-Bernabé, H Brunnström, J Huvila, ... EBioMedicine 65, 2021 | 31 | 2021 |
| Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma PHD Edqvist, J Huvila, B Forsström, L Talve, O Carpén, HB Salvesen, ... Gynecologic oncology 137 (3), 529-537, 2015 | 31 | 2015 |
| Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases A Jamieson, EF Thompson, J Huvila, S Leung, A Lum, C Morin, ... Gynecologic oncology 165 (2), 376-384, 2022 | 25 | 2022 |
| Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification A Jamieson, J Huvila, EF Thompson, S Leung, D Chiu, A Lum, ... Gynecologic oncology 165 (2), 201-214, 2022 | 24 | 2022 |
| The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: A European Network for Individualized Treatment of Endometrial Cancer … WJ Van Weelden, C Reijnen, HVN Küsters-Vandevelde, J Bulten, P Bult, ... Human Pathology 109, 80-91, 2021 | 24 | 2021 |
| Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death A Jamieson, J Huvila, D Chiu, EF Thompson, S Scott, S Salvador, D Vicus, ... Modern Pathology 36 (4), 100085, 2023 | 22 | 2023 |
| Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer SW Vrede, WJ Van Weelden, NCM Visser, J Bulten, LJM Van Der Putten, ... Gynecologic oncology 161 (3), 787-794, 2021 | 22 | 2021 |
| Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma J Huvila, TD Laajala, PH Edqvist, A Mardinoglu, L Talve, F Pontén, ... Gynecologic oncology 149 (1), 173-180, 2018 | 22 | 2018 |
| p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns EF Thompson, J Chen, J Huvila, J Pors, H Ren, J Ho, C Chow, M Ta, ... Modern Pathology 33 (9), 1649-1659, 2020 | 21 | 2020 |
| Molecular subtype diagnosis of endometrial carcinoma: Comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier J Huvila, K Orte, P Vainio, T Mettälä, T Joutsiniemi, S Hietanen Human Pathology 111, 98-109, 2021 | 17 | 2021 |
